These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11831643)

  • 1. Lineage-specific mechanism of drug and radiation resistance in melanoma mediated by tyrosinase-related protein 2.
    Pak BJ; Chu W; Lu SJ; Kerbel RS; Ben-David Y
    Cancer Metastasis Rev; 2001; 20(1-2):27-32. PubMed ID: 11831643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications.
    Chu W; Pak BJ; Bani MR; Kapoor M; Lu SJ; Tamir A; Kerbel RS; Ben-David Y
    Oncogene; 2000 Jan; 19(3):395-402. PubMed ID: 10656687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TYRP2-mediated resistance to cis-diamminedichloroplatinum (II) in human melanoma cells is independent of tyrosinase and TYRP1 expression and melanin content.
    Pak BJ; Li Q; Kerbel RS; Ben-David Y
    Melanoma Res; 2000 Oct; 10(5):499-505. PubMed ID: 11095412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation resistance of human melanoma analysed by retroviral insertional mutagenesis reveals a possible role for dopachrome tautomerase.
    Pak BJ; Lee J; Thai BL; Fuchs SY; Shaked Y; Ronai Z; Kerbel RS; Ben-David Y
    Oncogene; 2004 Jan; 23(1):30-8. PubMed ID: 14712208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of tyrosinase-related protein-2 (TYRP2) in human melanocytes: relationship to growth and morphology.
    Fang D; Kute T; Setaluri V
    Pigment Cell Res; 2001 Apr; 14(2):132-9. PubMed ID: 11310793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA repair pathways in drug resistance in melanoma.
    Bradbury PA; Middleton MR
    Anticancer Drugs; 2004 Jun; 15(5):421-6. PubMed ID: 15166615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosinase-related proteins suppress tyrosinase-mediated cell death of melanocytes and melanoma cells.
    Rad HH; Yamashita T; Jin HY; Hirosaki K; Wakamatsu K; Ito S; Jimbow K
    Exp Cell Res; 2004 Aug; 298(2):317-28. PubMed ID: 15265682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ascorbic acid increases the activity and synthesis of tyrosinase in B16F10 cells through activation of p38 mitogen-activated protein kinase.
    Lee SA; Son YO; Kook SH; Choi KC; Lee JC
    Arch Dermatol Res; 2011 Nov; 303(9):669-78. PubMed ID: 21667118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of tyrosinase, TRP-1 and TRP-2 in ultraviolet-irradiated human melanomas and melanocytes: TRP-2 protects melanoma cells from ultraviolet B induced apoptosis.
    Nishioka E; Funasaka Y; Kondoh H; Chakraborty AK; Mishima Y; Ichihashi M
    Melanoma Res; 1999 Oct; 9(5):433-43. PubMed ID: 10596909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EphB4 inhibitor overcome the acquired resistance to cisplatin in melanomas xenograft model.
    Yang X; Yang Y; Tang S; Tang H; Yang G; Xu Q; Wu J
    J Pharmacol Sci; 2015 Sep; 129(1):65-71. PubMed ID: 26390965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of targeted chemoradiotherapy for malignant melanoma by exploitation of metabolic pathway].
    Jimbow K
    Hokkaido Igaku Zasshi; 1998 Mar; 73(2):105-10. PubMed ID: 9612704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrinsic anticancer drug resistance of malignant melanoma cells is abrogated by IFN-β and valproic acid.
    Roos WP; Jöst E; Belohlavek C; Nagel G; Fritz G; Kaina B
    Cancer Res; 2011 Jun; 71(12):4150-60. PubMed ID: 21493591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human melanoma: drug resistance.
    Helmbach H; Sinha P; Schadendorf D
    Recent Results Cancer Res; 2003; 161():93-110. PubMed ID: 12528802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effect of Gastrodia elata extract on melanogenesis in HM3KO melanoma cells.
    Kim HJ; Lee JH; Shin MK; Hyun Leem K; Kim YJ; Lee MH
    J Cosmet Sci; 2013; 64(2):89-98. PubMed ID: 23578832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-(3,5-dimethylphenyl)-3-methoxybenzamide (A(3)B(5)) targets TRP-2 and inhibits melanogenesis and melanoma growth.
    Lee EJ; Lee YS; Hwang S; Kim S; Hwang JS; Kim TY
    J Invest Dermatol; 2011 Aug; 131(8):1701-9. PubMed ID: 21525883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incomplete expression of the tyrosinase gene family (tyrosinase, TRP-1, and TRP-2) in human malignant melanoma cells in vitro.
    Eberle J; Garbe C; Wang N; Orfanos CE
    Pigment Cell Res; 1995 Dec; 8(6):307-13. PubMed ID: 8789739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New thioureas and related substances intended for melanoma targeting.
    Mårs U; Larsson BS
    Pigment Cell Res; 1995 Aug; 8(4):194-201. PubMed ID: 8610070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of drug sensitivity and resistance in melanoma.
    La Porta CA
    Curr Cancer Drug Targets; 2009 May; 9(3):391-7. PubMed ID: 19442058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human melanoma cell lines show little relationship between expression of pigmentation genes and pigmentary behaviour in vitro.
    Eberle J; Wagner M; MacNeil S
    Pigment Cell Res; 1998 Jun; 11(3):134-42. PubMed ID: 9730320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT.
    Christmann M; Pick M; Lage H; Schadendorf D; Kaina B
    Int J Cancer; 2001 Apr; 92(1):123-9. PubMed ID: 11279615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.